Abstract
Background and Aim: Patients with severe aortic stenosis and reduced left ventricular ejection fraction (LVEF) have a poor prognosis compared with patients with preserved LVEF. To evaluate the impact of sutureless Perceval (LivaNova, Italy) aortic bioprosthesis on LVEF and clinical outcomes in patients with baseline left ventricular dysfunction underwent isolated aortic valve replacement. Methods: Between March 2011 and August 2017, 803 patients underwent AVR with Perceval bioprosthesis implantation. Fifty-two patients had preoperative LVEF ≤ 45%. Mean age of these patients was 77 ± 6 years, twenty-four patients were female (46%), and mean logistic EuroSCORE was 17.7 ± 10.2%. Perceval bioprosthesis was implanted in 9 REDO operations. In 43 patients (83%), AVR was performed in minimally invasive surgery with an upper ministernotomy (n = 13) or right anterior minithoracotomy (n = 30). Results: One patient died in-hospital. Cardiopulmonary bypass and aortic cross-clamp times were 98 ± 26 minutes and 61 ± 19 minutes, respectively. At mean follow-up of 33 ± 20 months (range: 1–75 months), survival was 90%, freedom from reoperation was 100%, and mean transvalvular pressure gradient was 11 ± 5 mmHg. LVEF improved from 37 ± 7% preoperatively to 43 ± 8% at discharge (p < 0.01) and further increased to 47 ± 9% at follow-up (p = 0.06), and moderate paravalvular leakage occurred in one patient without hemolysis not requiring any treatment. Conclusions: AVR with sutureless aortic bioprosthesis implantation in patients with preoperative left ventricular dysfunction demonstrated a significant immediate and early improvement in LVEF.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
